Discontinued — last reported Q4 '25
Intangibles (Net)
Merck & Co. Intangibles (Net) decreased by 99.1% to $140.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 97.2%, from $71.00M to $140.00M. Over 5 years (FY 2020 to FY 2025), Intangibles (Net) shows an upward trend with a 5.1% CAGR.
Analysis
How to read this metric
An increase often follows strategic acquisitions or significant R&D capitalization, while a decrease may indicate amortization or impairment charges.
Detailed definition
This represents the net book value of non-physical assets, such as patents, trademarks, software, and customer relations...
Peer comparison
Highly relevant for healthcare and technology firms; peers often disclose the composition of these assets in financial footnotes.
intangible_assets_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.62B | $13.38B | $0.00 | $23.02B | $22.50B | $21.37B | $0.00 | $19.86B | $19.67B | $19.20B | $18.01B | $17.57B | $16.98B | $17.01B | $71.00M | $15.76B | $15.19B | $15.31B | $140.00M |
| QoQ Change | — | -1.7% | -100.0% | — | -2.3% | -5.0% | -100.0% | — | -1.0% | -2.4% | -6.2% | -2.4% | -3.3% | +0.2% | -99.6% | >999% | -3.6% | +0.8% | -99.1% |
| YoY Change | — | — | — | — | +65.2% | +59.7% | — | -13.7% | -12.6% | -10.2% | — | -11.5% | -13.6% | -11.4% | -99.6% | -10.3% | -10.5% | -10.0% | +97.2% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Adempas | $445.00M | $431.00M | $372.00M | $353.00M | $348.00M | $312.00M | $280.00M | $239.00M |
| Alliance revenue - Lenvima | $563.00M | $502.00M | $442.00M | $382.00M | $321.00M | $261.00M | $201.00M | $188.00M |
| Keytruda Qlex | — | — | — | — | — | — | $930.00M | — |
| Ohtuvayre | — | — | — | — | — | — | $11.80B | — |
| Winrevair | — | — | $5.90B | — | — | — | $5.40B | — |
| Zerbaxa | — | — | $260.00M | — | — | — | — | — |
| Total | $16.98B | $17.01B | $71.00M | $15.76B | $15.19B | $15.31B | $140.00M | — |
Adempas, Alliance revenue - Lenvima, Keytruda Qlex, Ohtuvayre, Winrevair, Zerbaxa were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Intangibles (Net) at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s intangibles (net)?
- Merck & Co. (MRK) reported intangibles (net) of $140.00M in Q4 2025.
- How has Merck & Co.'s intangibles (net) changed year-over-year?
- Merck & Co.'s intangibles (net) increased by 97.2% year-over-year, from $71.00M to $140.00M.
- What is the long-term trend for Merck & Co.'s intangibles (net)?
- Over 5 years (2020 to 2025), Merck & Co.'s intangibles (net) has grown at a 5.1% compound annual growth rate (CAGR), from $109.00M to $140.00M.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and brands after accounting for amortization.